ERBB2 and cancer: The landscapes of oncogenic alterations in grade III ER+HER2− patients within benchmarked TCGA cohort bear different cancer driver events such as TP53 and ESR1, compared with low/intermediate grade cases, and one of their most prevalent mutation signatures was associated with defective DNA double‐strand break‐repair by homologous recombination.